Children's National Medical Center's transfusion protocol for sickle hemoglobinopathies

Immunohematology

Volumn 22, Issue 3, 2006, Pages 117-120

  Minniti, Caterina P ^a,b   Kratovil, Tonya ^c   Luban, Naomi L C ^a,b,d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d Laboratory Medicine and Pathology

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTIBODY;

ANTIBODY PRODUCTION; BLOOD BANK; BLOOD GROUP TYPING; CLINICAL PROTOCOL; ERYTHROCYTE TRANSFUSION; HEALTH CARE POLICY; HEALTH PROGRAM; HEMOGLOBINOPATHY; HUMAN; PEDIATRIC HOSPITAL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; UNITED STATES;

ANEMIA, SICKLE CELL; AUTOANTIBODIES; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; CHILD; HOSPITALS, PEDIATRIC; HUMANS; ISOANTIBODIES; PHENOTYPE;

EID: 33750477322     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Wang WC, Morales KH, Scher CD, et al. STOP Investigators. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. J Pediatr. 2005;147:244-7.
2. Adams RJ, Brambilla D. Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769-78.
3. Hawkins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106:2269-75.
4. Luban NL. Transfusion Formulae. Pediatric Transfusion Medicine, Volume 2, 1987. CRC Press, Boca Raton, FL.
5. Stroncek DF, Rainer T, Sharon V, et al. Sickle Hb polymerization in RBC components from donors with sickle cell trait prevents effective WBC reduction by filtration. Transfusion 2002;42:1466-72.
6. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The cooperative study of sickle cell disease. Blood 1990;76:1431-7.
7. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002;42:684-90.
8. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987;27:94-8.
9. Luban NL. Variability in rates of alloimmunization in different groups of children with sickle cell disease: effect of ethnic background. Am J Pediatr Hematol Oncol 1989;11:314-9.
10. Ofosu MD, Saunders DA, Dunston GM, et al. Association of HLA and autoantibody in transfused sickle cell disease patients. Am J Hematol 1986;22:27-33.
11. Vichinsky EP, Luban NL, Wright E, et al. Stroke prevention trial in sickle cell anemia. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41:1086-92.
12. Castellino SM, Combs MR, Zimmerman SA, et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol 1999;104:189-94.